Sales · healthcare · APACJul 202610 min read370 words

Sales enablement for Series B companies: scaling without breaking for healthcare and life sciences in the APAC region

How Series B companies scale sales enablement across regions and teams without losing the discipline that made it work at Series A. Written for commercial leaders at healthtech, medtech, and life-sciences companies in the APAC region.

This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in the APAC region. In this market, APAC buyers span very different cultures and reward vendors who adapt playbooks per market, so the way you install sales enablement has to be shaped to that reality from day one.

Series B is the stress test for sales enablement. What worked at fifteen people fails at fifty unless the operating rhythm is deliberate.

The Series B move is to separate the model owner from the operators. One senior human owns strategy, ramp time for new reps to first closed-won, and the weekly review; a small team runs the machine.

Add a second geography or segment only when the first one is producing a defensible number for two full quarters. Not before.

Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in the APAC region it is compounded by the fact that market-by-market adaptation, not one-size playbooks is what actually gates growth. Sales enablement is only useful here when it is pointed at both constraints at once.

Governance appears at Series B — that is fine, provided it accelerates rather than slows. The test is whether reviews still make decisions or just distribute updates.

The Series B failure mode of sales enablement is content libraries no one opens, amplified by headcount. Fix the root cause; do not paper over it with more people.

Compensation begins to matter now. Pay operators on ramp time for new reps to first closed-won outcomes, not on effort. Effort-based comp at Series B produces theatre.

A well-run sales enablement function at Series B is the moat that survives to Series C. Companies that skip this discipline burn through raises trying to buy it back.

Concretely for healthcare and life sciences in the APAC region: the healthcare teams that install this get past procurement instead of dying in it, and the APAC teams that install this stop treating the region as one market and start winning it as many. That is the reason it is worth installing sales enablement deliberately for this market rather than importing a playbook designed for somewhere else.

sales enablementsales collateralbattle cardssales enablement for series Bscaling GTMsales enablement for healthcare and life sciencessales enablement in the APAC regionhealthcare and life sciences growth in the APAC region

Frequently asked questions

Sales · healthcare · APAC — answered

Does sales enablement work for healthcare and life sciences in the APAC region?
Yes — provided it is pointed at regulated-sale cycle length, not intent and adapted to the fact that in the APAC region, APAC buyers span very different cultures and reward vendors who adapt playbooks per market. The healthcare teams that install this get past procurement instead of dying in it.
How does sales enablement change at Series B?
Ownership separates from execution; operating rhythm gets more deliberate; governance appears.
When should we expand to a second region?
After the first region delivers two straight quarters of defensible ramp time for new reps to first closed-won.
What compensation model works for sales enablement operators at Series B?
Outcome-linked on ramp time for new reps to first closed-won, not activity-based.
What is the Series B stress point?
Content libraries no one opens, amplified by headcount. Fix the root, not the symptom.
What is the APAC-specific pitfall when running sales enablement for healthcare?
Importing a playbook that was built for another market. In the APAC region, APAC buyers span very different cultures and reward vendors who adapt playbooks per market — the install has to reflect that.

Growth Broker editorial

Filed under sales · healthcare · apac

Up next

AI for Growth: the complete 2026 guide for B2B companies

Read piece

Ready to broker your growth?

Book a Growth Call